Literature DB >> 30875258

Zebrafish model of amyloid light chain cardiotoxicity: regeneration versus degeneration.

Shikha Mishra1,2, Shaurya Joshi1, Jennifer E Ward1, Eva P Buys2, Deepak Mishra3, Deepa Mishra1, Isabel Morgado1, Sudeshna Fisch1, Francesca Lavatelli4, Giampaolo Merlini4, Sharmila Dorbala2, Calum A MacRae2, Ronglih Liao1,2.   

Abstract

Cardiac dysfunction is the most frequent cause of morbidity and mortality in amyloid light chain (AL) amyloidosis caused by a clonal immunoglobulin light chain (LC). Previously published transgenic animal models of AL amyloidosis have not recapitulated the key phenotype of cardiac dysfunction seen in AL amyloidosis, which has limited our understanding of the disease mechanisms in vivo, as well as the development of targeted AL therapeutics. We have developed a transgenic zebrafish model in which a λ LC derived from a patient with AL amyloidosis is conditionally expressed in the liver under the control of the Gal4 upstream activation sequence enhancer system. Circulating LC levels of 125 µg/ml in these transgenic zebrafish are comparable to median pathological serum LC levels. Functional analysis links abnormal contractile function with evidence of cellular and molecular proteotoxicity in the heart, including increased cell death and autophagy. However, despite pathological and functional phenotypes analogous to human AL, the lifespan of the transgenic fish is comparable to control fish without the expressed AL-LC transgene. Nuclear labeling experiments suggest increased cardiac proliferation in the transgenic fish, which can be counteracted by treatment with a small molecule proliferation inhibitor leading to increased zebrafish mortality because of cardiac apoptosis and functional deterioration. This transgenic zebrafish model provides a platform to study underlying AL disease mechanisms in vivo further. NEW & NOTEWORTHY Heart failure is a major cause of mortality in amyloid light (AL) amyloidosis, yet it has been difficult to model in animals. We report the generation of a transgenic zebrafish model for AL amyloidosis with pathological concentration of circulating human light chain protein that results in cardiac dysfunction. The light chain toxicity triggers regeneration in the zebrafish heart resulting in functional compensation early in life, but with age develops into cardiac dysfunction.

Entities:  

Keywords:  amyloidosis; in vivo model cardiovascular disease; proteotoxicity; transgenic zebrafish

Mesh:

Substances:

Year:  2019        PMID: 30875258      PMCID: PMC6580397          DOI: 10.1152/ajpheart.00788.2018

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  28 in total

1.  Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation.

Authors:  Angela Dispenzieri; Martha Q Lacy; Jerry A Katzmann; S Vincent Rajkumar; Roshini S Abraham; Suzanne R Hayman; Shaji K Kumar; Raynell Clark; Robert A Kyle; Mark R Litzow; David J Inwards; Stephen M Ansell; Ivana M Micallef; Luis F Porrata; Michelle A Elliott; Patrick B Johnston; Philip R Greipp; Thomas E Witzig; Steven R Zeldenrust; Stephen J Russell; Dennis Gastineau; Morie A Gertz
Journal:  Blood       Date:  2006-01-05       Impact factor: 22.113

2.  Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL.

Authors:  Giovanni Palladini; Francesca Lavatelli; Paola Russo; Stefano Perlini; Vittorio Perfetti; Tiziana Bosoni; Laura Obici; Arthur R Bradwell; GianVico Melzi D'Eril; Roberto Fogari; Remigio Moratti; Giampaolo Merlini
Journal:  Blood       Date:  2006-01-24       Impact factor: 22.113

3.  The Tol2kit: a multisite gateway-based construction kit for Tol2 transposon transgenesis constructs.

Authors:  Kristen M Kwan; Esther Fujimoto; Clemens Grabher; Benjamin D Mangum; Melissa E Hardy; Douglas S Campbell; John M Parant; H Joseph Yost; John P Kanki; Chi-Bin Chien
Journal:  Dev Dyn       Date:  2007-11       Impact factor: 3.780

4.  Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989.

Authors:  R A Kyle; A Linos; C M Beard; R P Linke; M A Gertz; W M O'Fallon; L T Kurland
Journal:  Blood       Date:  1992-04-01       Impact factor: 22.113

5.  Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma.

Authors:  Sumit Madan; Angela Dispenzieri; Martha Q Lacy; Francis Buadi; Suzanne R Hayman; Steven R Zeldenrust; S Vincent Rajkumar; Morie A Gertz; Shaji K Kumar
Journal:  Mayo Clin Proc       Date:  2010-03       Impact factor: 7.616

6.  Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway.

Authors:  Jianru Shi; Jian Guan; Bingbing Jiang; Daniel A Brenner; Federica Del Monte; Jennifer E Ward; Lawreen H Connors; Douglas B Sawyer; Marc J Semigran; Thomas E Macgillivray; David C Seldin; Rodney Falk; Ronglih Liao
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-11       Impact factor: 11.205

7.  Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts.

Authors:  R Liao; M Jain; P Teller; L H Connors; S Ngoy; M Skinner; R H Falk; C S Apstein
Journal:  Circulation       Date:  2001-10-02       Impact factor: 29.690

Review 8.  Animal models of human amyloidoses: are transgenic mice worth the time and trouble?

Authors:  Joel N Buxbaum
Journal:  FEBS Lett       Date:  2009-07-20       Impact factor: 4.124

9.  Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis.

Authors:  Jun Koyama; Patricia A Ray-Sequin; Rodney H Falk
Journal:  Circulation       Date:  2003-05-12       Impact factor: 29.690

10.  In vivo studies of liver-type fatty acid binding protein (L-FABP) gene expression in liver of transgenic zebrafish (Danio rerio).

Authors:  Guor Mour Her; Chia-Chang Chiang; Wen-Ya Chen; Jen-Leih Wu
Journal:  FEBS Lett       Date:  2003-03-13       Impact factor: 4.124

View more
  6 in total

Review 1.  Molecular Mechanism of Pathogenesis and Treatment Strategies for AL Amyloidosis.

Authors:  Hidehiko Ikura; Jin Endo; Hiroki Kitakata; Hidenori Moriyama; Motoaki Sano; Keiichi Fukuda
Journal:  Int J Mol Sci       Date:  2022-06-06       Impact factor: 6.208

Review 2.  Amyloidosis in Heart Failure.

Authors:  Sandra Ihne; Caroline Morbach; Laura Obici; Giovanni Palladini; Stefan Störk
Journal:  Curr Heart Fail Rep       Date:  2019-12

Review 3.  Caenorhabditis elegans Models to Investigate the Mechanisms Underlying Tau Toxicity in Tauopathies.

Authors:  Carmina Natale; Maria Monica Barzago; Luisa Diomede
Journal:  Brain Sci       Date:  2020-11-11

4.  Light Chain Stabilization: A Therapeutic Approach to Ameliorate AL Amyloidosis.

Authors:  Gareth J Morgan; Joel N Buxbaum; Jeffery W Kelly
Journal:  Hemato       Date:  2021-10-05

5.  Autophagy Activation in Zebrafish Heart Regeneration.

Authors:  Myra N Chávez; Rodrigo A Morales; Camila López-Crisosto; Juan Carlos Roa; Miguel L Allende; Sergio Lavandero
Journal:  Sci Rep       Date:  2020-02-10       Impact factor: 4.379

Review 6.  Future Perspectives.

Authors:  Angela Dispenzieri; Giampaolo Merlini
Journal:  Hematol Oncol Clin North Am       Date:  2020-12       Impact factor: 3.722

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.